Please login or register to print this page.

VIEW TAGS

Articles tagged ‘new oral anticoagulants’

June 26, 2014

Increasing European uptake of ‘new’ oral anticoagulants

The new oral anticoagulants (NOACs) have being widely adopted throughout much of Europe, according to a report presented by Professor Jean-Yves Le Heuzey (Paris Descartes University) at Cardiostim 2014, held recently in Nice, France.

read more

May 28, 2014

NOAC advice for surgical patients

An overview of the major clinical trials and recommendations related to new oral anticoagulants, which aims to serve as a practical guide for their use in patients who require planned or emergency surgery, has been published recently in the British Journal of Surgery.1

read more

April 30, 2014

PREFER in AF patient registry extended

The PREFER in AF (PREvention oF thromboembolic events – European Registry in Atrial Fibrillation) registry has been extended to include a special focus on the use of novel oral anticoagulant (NOAC) therapy including prescribing patterns, providing new insight into the long-term management of patients with atrial fibrillation (AF).

read more

December 20, 2013

NOAC stroke protection in AF cuts across subgroups

Four new oral anticoagulants (NOACs) protect against stroke or systemic embolism better than warfarin, comparing favourably on safety in patients with atrial fibrillation (AF), according to a study1 published recently in The Lancet.

read more

April 26, 2013

ESC guide on new oral anticoagulants

A practical guide on the use of the new oral anticoagulants (NOACs) has been produced by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). The guide aims to summarise existing information on different drugs, to answer clinical questions that fall outside what drug companies can legally answer, and to make distinctions between the different drugs.

read more

May 24, 2012

New oral anticoagulants stake their claim

“New oral anticoagulants are poised to replace vitamin K antagonists for many patients with atrial fibrillation, and may have a role after acute coronary syndromes,” according to a review published recently in the Journal of the American College of Cardiology.1

read more

April 18, 2012

New oral anticoagulants eclipse warfarin in cost savings

Usage of the new oral anticoagulants (NOACs), dabigatran, rivaroxaban, and apixaban, may be associated with lower medical costs (excluding drug costs) relative to warfarin, according to results from the RE-LY, ROCKET-AF, and ARISTOTLE clinical trials. These were presented at the American College of Cardiology’s (ACC’s) 61st Annual Scientific Session, held recently in Chicago.

read more

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.